The MHRA has dismantled UK manufacturing operations producing fake retatrutide pens, and counterfeit products have been found to contain incorrect substances, including insulin
Tirzepatide becomes the preferred choice when patients experience plateaus on semaglutide, seek maximum weight reduction potential, or carry genetic markers favoring dual-pathway activation (particularly elevated GIPR or FTO variants)
Several FDA-approved weight-management medicines are already available for eligible patients
Healthcare providers can tailor a treatment plan that considers individual factors, including medical history, concurrent medications, and lifestyle
This illustration emphasizes the intricate nature of obesity and highlights the necessity for comprehensive strategies in treatment and prevention
doi: 10.1371/journal.pone.0196579